Wire Stories

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial…

3 years ago

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial…

3 years ago

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial…

3 years ago

NEW YORK & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has…

3 years ago

NEW YORK & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has…

3 years ago

NEW YORK & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has…

3 years ago

TOKYO--(BUSINESS WIRE)--WonderSpace Inc. (HO: Minato-ku, Tokyo; President: Naohiro Yamamoto) has launched "ANIME SAMURAI", a Japanese…

3 years ago

TOKYO--(BUSINESS WIRE)--WonderSpace Inc. (HO: Minato-ku, Tokyo; President: Naohiro Yamamoto) has launched "ANIME SAMURAI", a Japanese…

3 years ago

TOKYO--(BUSINESS WIRE)--WonderSpace Inc. (HO: Minato-ku, Tokyo; President: Naohiro Yamamoto) has launched "ANIME SAMURAI", a Japanese…

3 years ago

Digitalization, shift to remote work, and rise in state sponsored cyberattacks and espionage continue to…

3 years ago